7月23日（周三），美股盘中Abivax飙升至580%，其口服新药 Obefazimod 在溃疡性结肠炎 III 期诱导试验中取得积极结果，并计划向 FDA 提交申请。
消息面上，Abivax宣布其首创新型口服miR-124增强剂Obefazimod在中度至重度溃疡性结肠炎的ABTECT 8周诱导试验中取得积极的III期结果。公司还称准备在2026年下半年向FDA提交新药申请。
7月23日（周三），美股盘中Abivax飙升至580%，其口服新药 Obefazimod 在溃疡性结肠炎 III 期诱导试验中取得积极结果，并计划向 FDA 提交申请。
消息面上，Abivax宣布其首创新型口服miR-124增强剂Obefazimod在中度至重度溃疡性结肠炎的ABTECT 8周诱导试验中取得积极的III期结果。公司还称准备在2026年下半年向FDA提交新药申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.